ValGenesis logo
Verified via Expert Interviews

ValGenesis: Revenue, Valuation & Competitors

ValGenesis company overview

Ownership
PE-backed
Employees
622
Investors
Morgan Stanley Expansion Capital
Revenue / FTE
$6•k

About

Digital validation and risk management software for life sciences-focused companies, biotechs, and medical device companies to streamline the transition to digital validation processes and enhance risk management workflows.
Verified via Expert Interviews

Expert Vetted Data

Public disclosures rarely capture a company's internal dynamics or the true state of its technology. Gain first-hand insight by speaking with former ValGenesis executives.

Ownership & Key Financials

Revenue

$3•m '••
2

Investors

Morgan Stanley Expansion Capital
'21
1

Revenue / FTE

$6•k '••
2

Ownership

PE-backed
1

FTEs

2
+32% CAGR
176
2020
260
2021
393
2022
555
2023
622
2024

Legal Disclaimer

The company profiles displayed here are abridged, indicative previews of the full, proprietary data available within the Dialectica Origin Platform, derived from confidential sources and expert-vetted research. This content is the exclusive Intellectual Property (IP) of Dialectica. Your access does not grant any rights to the data. Systematic copying, scraping, crawling, indexing, or extraction, whether by manual means, automated software, bots, or Large Language Models (LLMs), is strictly prohibited and violates our Terms of Use.

This information is provided 'as is' for promotional purposes only; Dialectica disclaims all liability for its accuracy, completeness, or any reliance placed upon it.